ODN 2088 Control (ODN 20959)

TLR7/8/9 antagonists consist of short single-stranded oligodeoxynucleotides. They can inhibit CpG ODN-mediated activation of TLR9 and/or activation of TLR7/8.

ODN 2088 Control (ODN 20959) is a TLR7/8 antagonist but also acts as a TLR9 antagonist control. The sequence can form G-Tetrad structures.

Select a size:
Specifications for ODN 2088 Control (ODN 20959)
Overview

TLR7/8/9 antagonists consist of short single-stranded oligodeoxynucleotides. They can inhibit CpG ODN-mediated activation of TLR9 and/or activation of TLR7/8.

ODN 2088 Control (ODN 20959) is a TLR7/8 antagonist but also acts as a TLR9 antagonist control. The sequence can form G-Tetrad structures.

Detailed product information
Background information

TLR7, TLR8 and TLR9 are prominent members of the Toll-like-receptor (TLR) family recognizing pathogen-associated molecular patterns recognizing nucleic acids 3. Activation of these TLRs can be inhibited by short single-stranded synthetical oligodeoxyribonucleotides (ODNs) 4,6. Several classes of and motifs for inhibitory ODN have been identified 1,6,7.

Applications

TLR7/8/9 Antagonists can be used to inhibit TLR7/8/9 mediated cellular responses, such as activation of immune cells, human PBMCs, murine splenocytes or isolated immune cells (e.g., B cells and pDCs).

TLR7/8/9 Antagonists can be used to inhibit signaling in TLR7/8/9-

expressing recombinant cell lines.

ODN 2088 Control (ODN 20959) is can be used as a sequence control for ODN 2088 1,2,4-7. ODN 2088 Control (ODN 20959) inhibits TLR7 and TLR8 mediated signalling but not TLR9 mediated signalling 1.

Citations for ODN 2088 Control (ODN 20959)
Publications
  1. Kawai, T. and Akira, S. (2010) The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat Immunol 11 (5): 373-384
  2. Hackstein H. et al. (2011) The TLR7/8 ligand resiquimod targets monocyte-derived dendritic cell differentiation via TLR8 and augments functional dendritic cell generation. Cell. Immunol. 271: 401-412
  3. Lenert, P. et al. (2001) CpG stimulation of primary mouse B cells is blocked by inhibitory oligodeoxyribonucleotides at a site proximal to NF-kappaB activation. Antisense Nucleic Acid Drug Dev. 11: 247-256
  4. Jurk, M. et al. (2006) Modulating responsiveness of human TLR7 and 8 to small molecule ligands with T-rich phosphorothiate oligodeoxynucleotides. Eur. J. Immunol. 36: 1815-1826
  5. Lenert, P. S. (2010) Classification, mechanisms of action, and therapeutic applications of inhibitory oligonucleotides for Toll-like receptors (TLR) 7 and 9. Mediators Inflamm 2010: 986596
  6. Stunz, L. L. et al. (2002) Inhibitory oligonucleotides specifically block effects of stimulatory CpG oligonucleotides in B cells. Eur. J. Immunol. 32: 1212-1220
  7. Krieg, A. M. et al. (1998) Sequence motifs in adenoviral DNA block immune activation by stimulatory CpG motifs. Proc. Natl. Acad. Sci. U.S.A. 95: 12631-12636